Article

Serum anti-Spike antibody titers before and after heterologous booster with mRNA-1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine

2021-12-24

Abstract excerpt

<h4>Summary</h4> <h4>Background</h4> The inactivated whole-virus vaccine CoronaVac (SinoVac) is the COVID-19 vaccine most administered worldwide. However, data on its immunogenicity and reactogenicity to heterologous boosting with mRNA vaccines are lacking. <h4>Methods</h4> In a cohort of hospital staff in Jakarta, Indonesia, who received two-dose CoronaVac six months prior (median 190 days, IQR165-232), we measur...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6696984e-0e88-5e8d-8846-d1f4cdc3643f
DOI: 10.1101/2021.12.24.21268360

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Serum anti-Spike antibody titers before and after heterologous booster with mRNA-1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccineDOI 10.1101/2021.12.24.21268360Read

Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent VaccinesSemantic proximity Read

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim AnalysisSemantic proximity Read

Determinants of early antibody responses to COVID-19 mRNA vaccines in exposed and naive healthcare workersSemantic proximity Read

Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster VaccineSemantic proximity Read

Titers and Capacity of Neutralizing Antibodies Against SARS-CoV-2 Variants after Heterologous Booster Vaccination in Health Care Workers Primed with Two Doses of ChadOx1 nCov-19: A Single-Blinded, Randomized Clinical TrialSemantic proximity Read

Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccinationSemantic proximity Read

Differences in the concentration of anti-SARS-CoV-2 IgG antibodies post-COVID-19 recovery or post-vaccinationSemantic proximity Read

Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)Semantic proximity Read

Profiling antibody epitopes induced by mRNA-1273 vaccination and boostersSemantic proximity Read

Titers and capacity of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: a single-blinded, randomized clinical trialSemantic proximity Read

mRNA Vaccine-Induced SARS-CoV-2 Spike-Specific IFN-γ and IL-2 T-cell Responses are Predictive of Serological Neutralization and are Transiently Enhanced by Pre-Existing Cross-Reactive ImmunitySemantic proximity Read

Durability of Responses after SARS-CoV-2 mRNA-1273 VaccinationSemantic proximity Read